Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma

Anti-Cancer Drugs

Volumn 19, Issue 9, 2008, Pages 917-920

  Villela, Luis ^a,b,d   Garcia, Mauricio ^a   Caballero, Rocío ^a   Borbolla Escobozab, José R ^b   Bolaños Meade, Javier ^c  

^a Secretaria de Finanzas del Distrito Federal   (Mexico)

^b SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d ESCUELA DE MEDICINA Y CIENCIAS DE LA SALUD   (Mexico)

Author keywords

Central nervous system; Intrathecal therapy; Meningeal lymphomatosis; Non Hodgkin lymphoma; Targeted therapy

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER REGRESSION; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MANTLE CELL LYMPHOMA; MENINGEAL METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INJECTIONS, SPINAL; LYMPHOMA, MANTLE-CELL; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED;

EID: 52649139592     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32830cebc1     Document Type: Article

References (24)

1. Swerdlow SH, Berger F, Isaacson PI. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haemathopietic and lymphoid tissues. Lyon, France: IARC Press; 2001. pp. 168-170.
2. Segal GH, Masih AS, Fox AC, Jorgensen T, Scott M, Braylan MC. CD5-expressing B-cell non-Hodgkin's lymphomas with bcl-1 gene rearrangement have a relatively homogeneous immunophenotype and are associated with an overall poor prognosis. Blood 1995; 85:1570-1579.
3. Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82:567-575.
4. Zucca E, Roggero E, Pinotti G, Pedrinis E, Capella C, Venco A, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257-262.
5. Norton AJ, Matthews J, Pappa V, Shamash J, Love S, Rohatiner AZ, et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995; 6:249-256.
6. Fisher Rl, Dhalberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group Study. Blood 1995; 85:1075-1082.
7. Berger F, Felman P, Sonet A, Salles G, Bastion Y, Bryon PA, et al. Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical feature and outcome. Blood 1994; 83:2829-2835.
8. Bernard M, Gressin R, Leiré F, Drénuo B, Branger B, Caulet-Maugendre S, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 2001; 15:1785-1791.
9. Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Santkasing SU, et al. Central nervous system relapse in non-Hodgkin's lymphoma. A single-center study of 532 patients. Arch Neurol 1997; 54:854-859.
10. Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutierrez G, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2007; doi:10.1093/annonc/mdm447.
11. Valdez R, Kroft SH, Ross CW, Schnitzer B, Singleton T, Peterson LC, Finn WG. Cerebrospinal fluid involvement in mantle cell lymphoma. Mod Pathol 2002; 15:1073-1079.
12. Oinonen R, Franssila K. Elonen E. Central nervous system involvement in patients with mantle cell lyrnphoma. Ann Hematol 1999; 78: 145-149.
13. Montserrat E, Bosch F, Lopez Guillermo A, Graus F, Terol MJ, Rozman C. CNS involvement in mantle cell lyrnphoma. J Clin Oncol 1996; 14: 941-944.
14. Hedge U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, et al. High incidence of occult leptomeningeal disoase detected by flow cytometry in newly diagnosed aggressive B-cell lyrnphoma at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105:496-502.
15. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermontt M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101:466-468.
16. Schulz H, Pels H, Schimdt-Wolf I. Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lyrnphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 88:753-754.
17. Antonini G, Cox MC, Montefusco E, Ferrari A, Conte E, Morino S, et al. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lyrnphoma. J Neurooncol 2007; 81:197-199.
18. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lyrnphoma. J Clin Oncol 2007; 25: 1350-1356.
19. Manches O. Lui G, Chaperot L, Gressin R. Molons JP, Jacob MC, et al. In vitro mechanism of action of rituximab on primary non-Hodgkin's lyrnphoma. Blood 2003;101:949-954.
20. Harjunpäpä A, Wiklund T, Collan J, Janes R, Rosenberg J, Leo D. et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lyrnphoma. Leuk Lymphoma 2001; 42:731-738.
21. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large B-cell lyrnphoma: influence of rituximab. Ann Oncol 2004; 15:129-133.
22. Barnum SR. Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med 1995; 6:132-146.
23. Loeffler DA, Camp DM, Schonberger MB, Singer DJ, Lewitt PA. Early complement activation increases in the brain in some aged normal subjects. Neurobiol Aging 2004; 25:1001-1007.
24. Lindsberg PJ, Öhman J, Lehto T, Karjalainen-Lindsberg ML, Paetau A, Wuorimaa T, et al. Complement activation in the central nervous system following blood-brain barrier damage in man. Ann Neurol 1996; 40: 587-596.